- Axsome Therapeutics to Participate in Upcoming Investor Conferences
- Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function in Patients with Obstructive Sleep Apnea or Narcolepsy at SLEEP 2024
- Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Psychopharmacology Annual (ASCP) Meeting
- Axsome Therapeutics to Present at Upcoming Investor Conferences
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurology (AAN) 2024 Annual Meeting
- Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating Disorder
- Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Needs in Treated Narcolepsy Type 1 Patients
- Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narcolepsy
More ▼
Key statistics
On Friday, Axsome Therapeutics Inc (19X:DEU) closed at 67.32, 28.47% above the 52 week low of 52.40 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 67.70 |
---|---|
High | 69.54 |
Low | 67.32 |
Bid | 66.34 |
Offer | 69.06 |
Previous close | 69.20 |
Average volume | 625.30 |
---|---|
Shares outstanding | 47.50m |
Free float | 38.30m |
P/E (TTM) | -- |
Market cap | 3.49bn USD |
EPS (TTM) | -6.38 USD |
Data delayed at least 15 minutes, as of May 31 2024.
More ▼